Suppr超能文献

钠通道阻滞剂可增强Brugada综合征患者右胸前导联QT间期的时间变异性。

Sodium channel blockers enhance the temporal QT interval variability in the right precordial leads in Brugada syndrome.

作者信息

Kanemori Tetsuzou, Shimizu Hiroki, Oka Katsumi, Furukawa Yoshio, Hiromoto Kenji, Mine Takanao, Masuyama Tohru, Ohyanagi Mitsumasa

机构信息

Department of Internal Medicine, Division of Coronary Heart Disease, Hyogo College of Medicine, Nishinomiya, Japan.

出版信息

Ann Noninvasive Electrocardiol. 2008 Jan;13(1):74-80. doi: 10.1111/j.1542-474X.2007.00203.x.

Abstract

BACKGROUND

Temporal QT interval variability is associated with sudden cardiac death. The purpose of this study was to evaluate temporal QT interval variability in Brugada syndrome (BS).

METHODS

We measured QT and RR intervals in precordial leads (V(1)-V(6)) based on 12-beat resting ECG recordings from 16 BS patients (B group) with spontaneous ST elevation in right precordial leads (V(1)-V(2)) and from 10 patients with normal hearts (C group). We measured the response in B group before and after administration of pilsicainide (1 mg/kg). The standard deviation (QT-SD, RR-SD) of the time domain and total frequency power (QT-TP, RR-TP) were calculated for all precordial leads, and the latter was to analyze the frequency domain.

RESULTS

The right precordial leads in BS exhibited an additional and prominent ST elevation (coved-type) after pilsicainide administration. Both QT-SD and QT-TP values were significantly more increased in B, than in C (5.1 +/- 1.2 vs 3.6 +/- 0.2 and 23.4 +/- 2.9 vs 12.3 +/- 1.7 msec(2), P < 0.01, respectively) and after pilsicainide administration in B. (5.1 +/- 0.4 vs 3.9 +/- 0.3, 25.8 +/- 3.4 vs 16.3 +/- 2.6 msec(2), P < 0.01, respectively) However, QT-SD and QT-TP did not significantly change in any of other leads (V(3)-V(6)) and RR-SD and RR-TP were similar for both groups, as well as after intravenous pilsicainide administration in B.

CONCLUSIONS

The temporal QT interval variability was identified in BS. Moreover, sodium channel blocker induced temporal fluctuation in QT interval and it may possibly provide a substrate for ventricular arrhythmia in BS patients.

摘要

背景

QT间期的动态变化与心源性猝死相关。本研究旨在评估Brugada综合征(BS)患者的QT间期动态变化。

方法

我们基于16例右胸前导联(V(1)-V(2))有自发性ST段抬高的BS患者(B组)和10例心脏正常的患者(C组)静息状态下12个心动周期的心电图记录,测量胸前导联(V(1)-V(6))的QT间期和RR间期。我们测量了B组患者服用吡西卡尼(1mg/kg)前后的反应。计算所有胸前导联的时域标准差(QT-SD、RR-SD)和总频率功率(QT-TP、RR-TP),并通过后者分析频域。

结果

服用吡西卡尼后,BS患者的右胸前导联出现额外的、明显的ST段抬高(穹隆型)。B组的QT-SD和QT-TP值均显著高于C组(分别为5.1±1.2 vs 3.6±0.2和23.4±2.9 vs 12.3±1.7msec²,P<0.01),且B组服用吡西卡尼后也显著升高(分别为5.1±0.4 vs 3.9±0.3,25.8±3.4 vs 16.3±2.6msec²,P<0.01)。然而,其他导联(V(3)-V(6))的QT-SD和QT-TP均无显著变化,两组的RR-SD和RR-TP相似,B组静脉注射吡西卡尼后也相似。

结论

在BS患者中发现了QT间期的动态变化。此外,钠通道阻滞剂可引起QT间期的动态波动,这可能为BS患者的室性心律失常提供了基质。

相似文献

1
Sodium channel blockers enhance the temporal QT interval variability in the right precordial leads in Brugada syndrome.
Ann Noninvasive Electrocardiol. 2008 Jan;13(1):74-80. doi: 10.1111/j.1542-474X.2007.00203.x.
6
Ventricular arrhythmia induced by sodium channel blocker in patients with Brugada syndrome.
J Am Coll Cardiol. 2003 Nov 5;42(9):1624-31. doi: 10.1016/j.jacc.2003.06.004.
7
Incidence and initial characteristics of pilsicainide-induced ventricular arrhythmias in patients with Brugada syndrome.
Pacing Clin Electrophysiol. 2007 May;30(5):662-71. doi: 10.1111/j.1540-8159.2007.00728.x.
8
Clinical significance of macroscopic T-wave alternans after sodium channel blocker administration in patients with Brugada syndrome.
J Cardiovasc Electrophysiol. 2008 Jan;19(1):56-61. doi: 10.1111/j.1540-8167.2007.00967.x. Epub 2007 Oct 4.
9
Pilsicainide Administration Unmasks a Phenotype of Brugada Syndrome in a Patient with Overlap Syndrome due to the E1784K SCN5A Mutation.
Intern Med. 2020 Jan 1;59(1):83-87. doi: 10.2169/internalmedicine.3430-19. Epub 2019 Sep 3.
10
Prognostic Significance of the Sodium Channel Blocker Test in Patients With Brugada Syndrome.
J Am Heart Assoc. 2018 May 10;7(10):e008617. doi: 10.1161/JAHA.118.008617.

本文引用的文献

5
T wave alternans does not assess arrhythmic risk in patients with Brugada syndrome.
Ann Noninvasive Electrocardiol. 2004 Apr;9(2):162-5. doi: 10.1111/j.1542-474X.2004.92541.x.
6
Ventricular arrhythmia induced by sodium channel blocker in patients with Brugada syndrome.
J Am Coll Cardiol. 2003 Nov 5;42(9):1624-31. doi: 10.1016/j.jacc.2003.06.004.
7
Intravenous administration of class I antiarrhythmic drug induced T wave alternans in an asymptomatic Brugada syndrome patient.
Pacing Clin Electrophysiol. 2003 Sep;26(9):1900-3. doi: 10.1046/j.1460-9592.2003.00288.x.
8
Risk stratification for asymptomatic patients with Brugada syndrome.
Circ J. 2003 Apr;67(4):312-6. doi: 10.1253/circj.67.312.
10
Proposed diagnostic criteria for the Brugada syndrome: consensus report.
Circulation. 2002 Nov 5;106(19):2514-9. doi: 10.1161/01.cir.0000034169.45752.4a.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验